UMIN ID: C000000375
Registered date:01/04/2006
A combination of prednisolone, mizoribine, warfarin and dipyridamole for IgA nephropathy with nephrotic syndrome and diffuse mesangial proliferation in children.
Basic Information
Recruitment status | Complete: follow-up complete |
---|---|
Health condition(s) or Problem(s) studied | IgA nephropathy in children |
Date of first enrollment | 1998/08/01 |
Target sample size | 20 |
Countries of recruitment | Japan |
Study type | Interventional |
Intervention(s) | prednisolone+mizoribine+warfarin+dipyridamole for 2 years |
Outcome(s)
Primary Outcome | Disappearance rate of proteinuria |
---|---|
Secondary Outcome |
Key inclusion & exclusion criteria
Age minimum | 2years-old |
---|---|
Age maximum | 18years-old |
Gender | Male and Female |
Include criteria | |
Exclude criteria | 1.Other renal or systemic forms of nephrotic syndrome defined on renal biopsy, clinical features or serology (Henoch-Schönlein nephritis, systemic lupus erythematosus). 2.Medical history of allergy or hypersensitivity reactions to prednisolone, mizorobine, warfarin or dipyridamole 3.Chronic renal dysfunction 4.Active infectious disease 5.Severe liver disfunction 6.History of corticosteroid and immunosupression administration 7.Pregnancy 8.Judged inappropriate for this study by the physicians |
Related Information
Primary Sponsor | The Japanese Pediatric IgA Nephropathy of Treatment Study Group |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | The Kidney Foundation, Japan |
Secondary ID(s) |
Contact
public contact | |
Name | Koichi Nakanishi |
Address | 811-1 Kimiidera Wakayama City Wakayama Japan |
Telephone | |
Affiliation | The Japanese Pediatric IgA Nephropathy of Treatment Study Group Department of Pediatrics, Wakayama Medical University |
scientific contact | |
Name | Norishige Yoshikawa |
Address | 811-1 Kimiidera Wakayama City Wakayama Japan |
Telephone | |
Affiliation | Wakayama Medical University Department of Pediatrics |